There’s no evidence a new sublineage of the Delta variant is having any significant effect in the United States, US Centers for Disease Control and Prevention director Dr. Rochelle Walensky said Wednesday.
While the AY 4.2 coronavirus subvariant has been identified in the United States, it’s not growing in frequency or causing clusters, Walensky told a White House Covid-19 briefing.
“At this time, there is no evidence that the sublineage AY 4.2 impacts the effectiveness of our current vaccines or therapeutics,” she said.
"There are new variants that continue to emerge as cases continue to spread, and in particular, the AY 4.2 variant has drawn some attention in recent days. AY 4.2 is a sublineage of the Delta variant that has been recently identified in the UK, and we have on occasion identified this sublineage here in the United States, but not with recent increased frequency or clustering to date," Walensky said.
"CDC is continuing to track lineages and sublineages of Delta, and all other variants," Walensky said. "We particularly monitor for sublineages that could impact therapeutics, such as monoclonal antibodies and vaccines.”